Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...

Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company ...

BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Valeant got into trouble nearly a decade ago after using debt to ...

Trukera Medical, whose executive chairman is well-known Orange County executive Jim Mazzo, announced last month that it has been acquired by global eye health company Bausch + Lomb Corp. for an ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Milestone® (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its ...

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial ...